Table 3:

Demographic and Clinical Factors for Azathioprine Patient Group^*

		rs4149117
Genotype		GG (n=30)	TT/GT (n=15)	p-value
Recipient Factors	Age (years, mean ±SD)	48.6 ±16.2	49.4 ± 13.9	0.971
	Female Gender, n (%)	13 (43.3)	8 (53.3)	0.526
	Race, n (%)			0.041
	White	30 (100)	13 (86.7)
	Non-White	0 (0)	2 (13.3)
	Diagnosis, n (%)			0.701
	ILD	7 (23.3)	5 (33.3)
	COPD	8 (26.7)	5 (33.3)
	Cystic Fibrosis	9 (30.0)	2 (13.3)
	A1AT	2 (6.7)	1 (6.7)
	Sarcoidosis	0 (0)	1 (6.7)
	Other	4 (13.3)	1 (6.7)
	LAS, median (IQR)	43.67 (33.17–50.13)	38.67 (35.39–48.33)	0.246
Donor Factors	Age, years (mean ±SD)	35.1 ± 14.4	33.1 ± 13.2	0.782
	Female Gender, n (%)	15 (50)	5 (33.3)	0.289
	Race, n (%)			0.612
	White	24 (80)	11 (73.3)
	Non-White	6 (20)	4 (26.7)
Transplant Factors	Transplant Type			0.153
	Bilateral	30 (10)	14 (93.3)
	Single	0 (0)	1 (6.7)
	Cardiopulmonary Bypass	9 (30)	5 (33.3)	0.820
	Ischemic Time, min (mean ± SD)	280.77 ± 66.03	282.20 ± 62.96	0.754
	PGD at 72 hours			0.205
	0	8 (26.7)	3 (20)
	1	21 (70)	9 (60)
	2	1 (3.3)	1 (6.7)
	3	0 (0)	2 (13.3)
	Calcineurin Inhibitor			0.041
	Tacrolimus	30 (100)	13 (86.6)
	Cyclosporine	0 (0)	2 (13.3)
	Any Acute Rejection at 1 Year, n (%)	20 (66.7)	8 (53.3)	0.384

^*rs4149117 and rs7311358 demonstrated complete linkage disequilibrium in the Azathioprine group, therefore, demographics are only reported for rs4149117.

ILD: Interstitial lung disease, COPD: chronic obstructive pulmonary disease, A1AT: alpha-1 antitrypsin, LAS: lung allocation score, PGD: primary graft dysfunction